Company: IXHL
Filing Date: 2025-10-27
Form Type: DEF 14A
Source: 0001213900-25-102654
Chunk: 35

Company: Incannex Healthcare Inc.
Filing Date: 2025-10-27
Form: DEF 14A
Chunk 35
---
 its responsibilities for the financial statements for the fiscal year ended June 30, 2025, the audit committee took the following actions:

| ● | Discussed with Grant Thornton the matters required to be discussed                        
 in accordance with Auditing Standard No. 1301 — Communications with Audit Committees; and |

| ● | Received written disclosures and the letter from Grant Thornton regarding                                                                       
 its independence as required by applicable requirements of the Public Company Accounting Oversight Board regarding Grant Thornton’s             
 communications with the audit committee concerning independence and the audit committee further discussed with Grant Thornton its independence. 
 The audit committee also considered the status of pending litigation, taxation matters and other areas of oversight relating to the financial   
 reporting and audit process that the committee determined appropriate.                                                                          |

Based on the audit committee’s review of the audited financial statements and discussions with management, Grant Thornton, the audit committee recommended to the board of directors that the audited financial statements be included in our annual report on Form 10-K for the fiscal year ended June 30, 2025 for filing with the SEC.

| Members of the Incannex Healthcare Inc. Audit Committee |
| Peter Widdows (Chairperson)                             |
| Robert Clark                                            |
| Dr. George Anastassov                                   |

24 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS There were no related person transactions that would require disclosure under Item 404 of Regulation S-K. Compensation arrangements between our directors and named executive officers are described in the section entitled “Executive Officer and Director Compensation.” Policies and Procedures for Related Party Transactions On October 5, 2023, the Company adopted a written Related Person Transaction Policy. This policy applies to any transaction in which the Company and a director, a director’s nominee, an executive officer, any beneficial owner of at least 5% of the shares of common stock or an immediate family member of any of the foregoing are a party, and the amount involved exceeds $120,000. The policy provides that the board of directors must review the details of such transaction and approve it. If a related person transaction was not approved prior to its execution, the board of directors must either ratify the transaction or rescind it. The board of directors considers all information that it deems relevant when evaluating the transaction, including, but not limited to, the extent of the related person’s interest in the transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar circumstances.